Marble Wealth LLC Invests $2.95 Million in Johnson & Johnson $JNJ

Marble Wealth LLC acquired a new position in Johnson & Johnson (NYSE:JNJ) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 14,254 shares of the company’s stock, valued at approximately $2,950,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Plancorp LLC increased its stake in shares of Johnson & Johnson by 0.3% in the fourth quarter. Plancorp LLC now owns 15,889 shares of the company’s stock worth $3,288,000 after purchasing an additional 45 shares in the last quarter. Baron Silver Stevens Financial Advisors LLC increased its stake in shares of Johnson & Johnson by 0.8% in the fourth quarter. Baron Silver Stevens Financial Advisors LLC now owns 5,645 shares of the company’s stock worth $1,168,000 after purchasing an additional 45 shares in the last quarter. Strategic Financial Services Inc. increased its stake in shares of Johnson & Johnson by 0.5% in the fourth quarter. Strategic Financial Services Inc. now owns 8,995 shares of the company’s stock worth $1,862,000 after purchasing an additional 45 shares in the last quarter. WealthCollab LLC increased its stake in shares of Johnson & Johnson by 4.7% in the fourth quarter. WealthCollab LLC now owns 1,015 shares of the company’s stock worth $210,000 after purchasing an additional 46 shares in the last quarter. Finally, MMA Asset Management LLC raised its position in shares of Johnson & Johnson by 1.3% during the fourth quarter. MMA Asset Management LLC now owns 3,600 shares of the company’s stock valued at $745,000 after buying an additional 46 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Down 0.2%

Shares of JNJ opened at $223.00 on Wednesday. The company’s fifty day moving average is $232.75 and its 200 day moving average is $225.29. Johnson & Johnson has a fifty-two week low of $149.04 and a fifty-two week high of $251.71. The stock has a market capitalization of $536.81 billion, a PE ratio of 25.78, a P/E/G ratio of 2.19 and a beta of 0.26. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.68 by $0.02. The company had revenue of $24.06 billion during the quarter, compared to analyst estimates of $23.60 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. Johnson & Johnson’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Sell-side analysts expect that Johnson & Johnson will post 11.57 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be paid a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, May 26th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 annualized dividend and a yield of 2.4%. Johnson & Johnson’s payout ratio is presently 61.97%.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: CNBC’s Jim Cramer pointed to Johnson & Johnson as one of five stocks to buy for diversification outside the AI trade, which could attract investors looking for lower-volatility, defensive exposure. Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification
• Positive Sentiment: Scotiabank reiterated its Buy rating on Johnson & Johnson, reinforcing Wall Street confidence in the company’s earnings durability and dividend appeal. Scotiabank Sticks to Their Buy Rating for Johnson & Johnson (JNJ)
• Positive Sentiment: Several articles highlighted JNJ as one of the best dividend-paying stocks to own, which can support the stock as investors favor income and defensive healthcare names. Is Johnson & Johnson (JNJ) One of the Best Dividend Paying Stocks to Buy Right Now?
• Neutral Sentiment: Recent commentary also questioned whether Johnson & Johnson’s strong one-year rally leaves limited upside near current levels, suggesting valuation could temper enthusiasm. Is It Too Late To Consider Johnson & Johnson (JNJ) After Its 48% One-Year Surge?
• Neutral Sentiment: A Motley Fool piece argued JNJ’s effort to challenge AbbVie’s growth driver should not alarm AbbVie shareholders, implying the competitive angle is not a major near-term negative for Johnson & Johnson itself. Johnson & Johnson Hopes to Dethrone AbbVie’s Biggest Growth Driver. Here’s Why Investors Shouldn’t Panic

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent analyst reports. Morgan Stanley set a $283.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, April 15th. Weiss Ratings cut shares of Johnson & Johnson from a “buy (b+)” rating to a “buy (b)” rating in a research report on Friday, April 24th. Citigroup lifted their price objective on shares of Johnson & Johnson from $274.00 to $285.00 and gave the company a “buy” rating in a research report on Tuesday, April 7th. Royal Bank Of Canada reiterated an “outperform” rating and set a $265.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, April 15th. Finally, Rothschild & Co Redburn lifted their price objective on shares of Johnson & Johnson from $180.00 to $210.00 and gave the company a “neutral” rating in a research report on Thursday, February 19th. Twenty analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $253.04.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.